Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Innate Pharma (IPHA) EBT Margin (2020 - 2024)

Innate Pharma posted quarterly EBT Margin of 391.94% for Q4 2024, down 37736.0% year-on-year from N/an in Q1 2024, and down 31.25% on a QoQ basis from 298.61% in Q2 2024.

Innate Pharma (IPHA) has 5 years of EBT Margin data on file, last reported at 391.94% in Q4 2024.

  • For the quarter ending Q4 2024, EBT Margin fell 37736.0% year-over-year to 391.94%; the trailing twelve-month figure through Dec 2024 stood at 74.57% (down 4171.0% YoY), and the FY2025 full-year result was 1764.51%, down 151865.0% from the prior year.
  • EBT Margin for Q4 2024 stood at 391.94%, down from 298.61% in the prior quarter.
  • Across five years, EBT Margin topped out at 1.61% in Q2 2023 and bottomed at 391.94% in Q4 2024.
  • The 5-year median for EBT Margin is 14.59% (2023), against an average of 127.03%.
  • The widest annual swing landed in 2022, when EBT Margin surged 18400 bps; it then tumbled 37736 bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 1.48% in 2020, then plunged by 12371 bps to 184.1% in 2021, then surged by 100 bps to 0.1% in 2022, then plunged by 14410 bps to 14.59% in 2023, then tumbled by 2587 bps to 391.94% in 2024.
  • The last three EBT Margin figures came in at 391.94% (Q4 2024), 298.61% (Q2 2024), and 14.59% (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn -6.43%
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 41.95%
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 23.05%
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 18.99%
10 Innate Pharma 199.64 Mn 199.64 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 -391.94%
Jun 30, 2024 -298.61%
Dec 31, 2023 -14.59%
Jun 30, 2023 1.61%
Dec 31, 2022 -0.10%
Dec 31, 2021 -184.10%
Dec 31, 2020 -1.48%